Researchers at Columbia University Mailman School of Public Health have developed a computational pipeline to identify protein biomarkers associated with complex diseases like Alzheimer’s disease. The pipeline analyzes biomarkers that induce 3D structural changes in proteins, providing insights into disease mechanisms and potential therapeutic targets. The study identified seven key proteins linked to Alzheimer’s risk and suggested that FDA-approved drugs targeting these proteins could be repurposed for treatment. The novel pipeline, MR-SPI, does not require a large number of genetic markers and can predict 3D structural changes caused by genetic mutations, offering opportunities for drug discovery and treatment advancements for Alzheimer’s and other complex diseases.
Source link
New computational pipeline identifies key biomarkers for Alzheimer’s disease
